NeuBase Therapeutics, Inc.
NASDAQ: NBSE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Todd P. Branning
- Employees
- 37
- Headquarters
- Pittsburgh, United States
- IPO year
- 2004
- Market cap
- $1.4M
- Website
- https://www.neubasetherapeutics.com
Loading NBSE…
Loading profile data…Frequently asked questions about NBSE
What does NeuBase Therapeutics, Inc. (NBSE) do?
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being uti...
Where does NBSE trade?
NeuBase Therapeutics, Inc. (NBSE) trades on the NASDAQ Capital Market.
What sector is NBSE in?
NeuBase Therapeutics, Inc. (NBSE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NeuBase Therapeutics, Inc.?
Todd P. Branning is the chief executive officer of NeuBase Therapeutics, Inc. (NBSE).
Where is NeuBase Therapeutics, Inc. headquartered?
NeuBase Therapeutics, Inc. is headquartered in United States.
Does NBSE pay a dividend?
NeuBase Therapeutics, Inc. (NBSE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NBSE go public?
NeuBase Therapeutics, Inc. (NBSE) completed its initial public offering in 2004.